Here we developed a de novo glioblastoma multiforme model derived from immortalized human neural stem/progenitor cells (hNSCs) to enable precise system-level comparisons of pre-malignant and oncogene-induced malignant states of NSCs. This work identified the niche required for glioma stem cell growth in the brain. Read the Abstract Download the PDF
For several years now, the American health-care system has been undergoing a transformation. Innovative ideas are being explored, new systems continue to be created, and millions of lives have been impacted. As health-care providers and research engines, academic institutions have an opportunity not only to push the frontiers of knowledge but also to test new
Reducing Drug Costs by Increasing Science-Driven Drug Discovery Read More »
One billion lives. That is the estimated human death toll of tobacco use in the 21st century. Tobacco use is the leading cause of preventable death worldwide—20% of all deaths and 30% of cancer deaths in the United States are linked to tobacco use. Impacting this preventable public health menace requires policy, education, and cessation
Supporting Policy to Reduce Tobacco-Related Deaths Read More »
Deep knowledge of immunology, cancer biology, and disruptive technology in computational science and molecular profiling has positioned us to dethrone the emperor of all maladies. The cancer research community is prepared to fulfill President Barack Obama’s call for a national cancer moonshot aimed at eradicating cancer. Elevating cancer to a national priority has given hope
Dethroning the Emperor of All Maladies Read More »
When it comes to bioscience and biotechnology innovation, Texas has made significant investments and advances in recent years. But more must be done. Chronic diseases such as cancer, heart disease, stroke and diabetes are responsible for between 60 and 70 percent of all deaths in Texas. Treating chronic disease accounts for 86 percent of our
Medical Innovation: A Policy Priority in Texas Read More »
In this perspective, we review the novel concept of “collateral lethality”, which has served to identify cancer-specific therapeutic vulnerabilities resulting from co-deletion of passenger genes neighboring tumor suppressor genes. Read the Abstract Download the PDF
Collateral Lethality: A New Therapeutic Strategy in Oncology Read More »
If you know a certain product has the ability to stunt your growth, cause cancer or even kill you, would you use it? The likely answer is no, yet 40 million Americans continue to smoke today. For the last 50 years, tobacco control efforts have saved an estimated eight million livesin the United States alone.
Missed Opportunity: What if we Raised the Minimum Age to Buy Tobacco Products Read More »
Ronald A. DePinho, M.D., president of The University of Texas MD Anderson Cancer Center, sat down with Texas Medical Center Executive Vice President and Chief Strategy and Operating Officer William F. McKeon to look back on the influences that led him to medicine, and how passion and dedication drive the MD Anderson team in their
In this paper, we provide genetic evidence that telomere dysfunction-induced DNA damage drives classical myelodysplastic syndrome phenotypes and alters common myeloid progenitor differentiation by repressing the expression of mRNA splicing/processing genes. This study established an intimate link across telomere biology, aberrant RNA splicing, and myeloid progenitor differentiation. Read the Abstract Download the PDF
Drs. Francis Collins and Ronald DePinho talk about the state of cancer research, the process of converting scientific discoveries into drug therapies, and how close a cure may be. Topics included the demographic impact of cancer and preventative measures such as vaccinations and whether future vaccines should be mandatory. Watch the Video
Aspen Institute: The State of Cancer Research Read More »
Sign up for the latest news and updates from Ron DePinho, MD
